nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Capecitabine—esophageal cancer	0.0422	0.665	CbGbCtD
Epoprostenol—CYP2C9—Cisplatin—esophageal cancer	0.0213	0.335	CbGbCtD
Epoprostenol—PTGIS—smooth muscle tissue—esophageal cancer	0.0109	0.183	CbGeAlD
Epoprostenol—P2RY12—epithelium—esophageal cancer	0.0101	0.171	CbGeAlD
Epoprostenol—Septicemia—Methotrexate—esophageal cancer	0.00833	0.0286	CcSEcCtD
Epoprostenol—Pain in jaw—Capecitabine—esophageal cancer	0.00779	0.0268	CcSEcCtD
Epoprostenol—PTGIS—lung—esophageal cancer	0.00716	0.121	CbGeAlD
Epoprostenol—PTGIR—epithelium—esophageal cancer	0.00647	0.109	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—esophageal cancer	0.00624	0.105	CbGeAlD
Epoprostenol—Ascites—Capecitabine—esophageal cancer	0.00559	0.0192	CcSEcCtD
Epoprostenol—Chest tightness—Capecitabine—esophageal cancer	0.00542	0.0186	CcSEcCtD
Epoprostenol—Pneumothorax—Capecitabine—esophageal cancer	0.0051	0.0175	CcSEcCtD
Epoprostenol—PTGIR—digestive system—esophageal cancer	0.00493	0.0829	CbGeAlD
Epoprostenol—PTGIS—lymph node—esophageal cancer	0.0049	0.0825	CbGeAlD
Epoprostenol—Platelet count decreased—Capecitabine—esophageal cancer	0.00427	0.0147	CcSEcCtD
Epoprostenol—Infection—Carboplatin—esophageal cancer	0.00416	0.0143	CcSEcCtD
Epoprostenol—PTGIR—lung—esophageal cancer	0.00411	0.0693	CbGeAlD
Epoprostenol—Cellulitis—Cisplatin—esophageal cancer	0.00379	0.013	CcSEcCtD
Epoprostenol—Hypercalcaemia—Capecitabine—esophageal cancer	0.00366	0.0126	CcSEcCtD
Epoprostenol—Pain—Carboplatin—esophageal cancer	0.00358	0.0123	CcSEcCtD
Epoprostenol—Hyperkalaemia—Cisplatin—esophageal cancer	0.00338	0.0116	CcSEcCtD
Epoprostenol—Pleural effusion—Capecitabine—esophageal cancer	0.00332	0.0114	CcSEcCtD
Epoprostenol—Body temperature increased—Carboplatin—esophageal cancer	0.00331	0.0114	CcSEcCtD
Epoprostenol—Skin ulcer—Capecitabine—esophageal cancer	0.00326	0.0112	CcSEcCtD
Epoprostenol—Hyperaesthesia—Capecitabine—esophageal cancer	0.00324	0.0111	CcSEcCtD
Epoprostenol—Injection site pain—Capecitabine—esophageal cancer	0.00311	0.0107	CcSEcCtD
Epoprostenol—Hypoxia—Methotrexate—esophageal cancer	0.00298	0.0102	CcSEcCtD
Epoprostenol—Chest discomfort—Capecitabine—esophageal cancer	0.00287	0.00986	CcSEcCtD
Epoprostenol—PTGIR—lymph node—esophageal cancer	0.00281	0.0474	CbGeAlD
Epoprostenol—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00281	0.00966	CcSEcCtD
Epoprostenol—Cellulitis—Capecitabine—esophageal cancer	0.00279	0.0096	CcSEcCtD
Epoprostenol—Cyanosis—Methotrexate—esophageal cancer	0.00267	0.00918	CcSEcCtD
Epoprostenol—Neck pain—Capecitabine—esophageal cancer	0.00257	0.00883	CcSEcCtD
Epoprostenol—Pulmonary embolism—Capecitabine—esophageal cancer	0.00254	0.00873	CcSEcCtD
Epoprostenol—Injection site reaction—Capecitabine—esophageal cancer	0.00252	0.00867	CcSEcCtD
Epoprostenol—Pleural effusion—Methotrexate—esophageal cancer	0.00247	0.00848	CcSEcCtD
Epoprostenol—Influenza like illness—Capecitabine—esophageal cancer	0.00247	0.00847	CcSEcCtD
Epoprostenol—Skin ulcer—Methotrexate—esophageal cancer	0.00243	0.00834	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00228	0.00785	CcSEcCtD
Epoprostenol—Sepsis—Capecitabine—esophageal cancer	0.0022	0.00757	CcSEcCtD
Epoprostenol—Abdominal discomfort—Cisplatin—esophageal cancer	0.00207	0.00712	CcSEcCtD
Epoprostenol—Pancytopenia—Cisplatin—esophageal cancer	0.00205	0.00705	CcSEcCtD
Epoprostenol—Hepatic failure—Capecitabine—esophageal cancer	0.00205	0.00705	CcSEcCtD
Epoprostenol—Thirst—Capecitabine—esophageal cancer	0.00194	0.00666	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Cisplatin—esophageal cancer	0.0019	0.00653	CcSEcCtD
Epoprostenol—Arthritis—Capecitabine—esophageal cancer	0.0019	0.00652	CcSEcCtD
Epoprostenol—Pulmonary embolism—Methotrexate—esophageal cancer	0.00189	0.0065	CcSEcCtD
Epoprostenol—Myocardial infarction—Cisplatin—esophageal cancer	0.00189	0.00649	CcSEcCtD
Epoprostenol—Cardiac failure—Capecitabine—esophageal cancer	0.00189	0.00649	CcSEcCtD
Epoprostenol—Bradycardia—Cisplatin—esophageal cancer	0.00176	0.00605	CcSEcCtD
Epoprostenol—CYP2C9—digestive system—esophageal cancer	0.00176	0.0296	CbGeAlD
Epoprostenol—Connective tissue disorder—Cisplatin—esophageal cancer	0.0017	0.00584	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00168	0.00578	CcSEcCtD
Epoprostenol—Pulmonary oedema—Methotrexate—esophageal cancer	0.00168	0.00578	CcSEcCtD
Epoprostenol—Sepsis—Methotrexate—esophageal cancer	0.00164	0.00564	CcSEcCtD
Epoprostenol—Gastritis—Capecitabine—esophageal cancer	0.00163	0.00561	CcSEcCtD
Epoprostenol—Flushing—Cisplatin—esophageal cancer	0.00161	0.00552	CcSEcCtD
Epoprostenol—Cardiac disorder—Cisplatin—esophageal cancer	0.00161	0.00552	CcSEcCtD
Epoprostenol—Abdominal distension—Capecitabine—esophageal cancer	0.0016	0.00551	CcSEcCtD
Epoprostenol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00156	0.00536	CcSEcCtD
Epoprostenol—Abdominal discomfort—Capecitabine—esophageal cancer	0.00153	0.00525	CcSEcCtD
Epoprostenol—Hepatic failure—Methotrexate—esophageal cancer	0.00153	0.00525	CcSEcCtD
Epoprostenol—Pancytopenia—Capecitabine—esophageal cancer	0.00151	0.0052	CcSEcCtD
Epoprostenol—Flatulence—Cisplatin—esophageal cancer	0.00148	0.0051	CcSEcCtD
Epoprostenol—Muscle spasms—Cisplatin—esophageal cancer	0.00145	0.00497	CcSEcCtD
Epoprostenol—Weight decreased—Capecitabine—esophageal cancer	0.00144	0.00495	CcSEcCtD
Epoprostenol—Pneumonia—Capecitabine—esophageal cancer	0.00143	0.00491	CcSEcCtD
Epoprostenol—Infestation NOS—Capecitabine—esophageal cancer	0.00142	0.00488	CcSEcCtD
Epoprostenol—Infestation—Capecitabine—esophageal cancer	0.00142	0.00488	CcSEcCtD
Epoprostenol—Depression—Capecitabine—esophageal cancer	0.00142	0.00487	CcSEcCtD
Epoprostenol—Tremor—Cisplatin—esophageal cancer	0.00141	0.00485	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Capecitabine—esophageal cancer	0.0014	0.00481	CcSEcCtD
Epoprostenol—Myocardial infarction—Capecitabine—esophageal cancer	0.00139	0.00478	CcSEcCtD
Epoprostenol—Anaemia—Cisplatin—esophageal cancer	0.00139	0.00478	CcSEcCtD
Epoprostenol—Urinary tract infection—Capecitabine—esophageal cancer	0.00138	0.00474	CcSEcCtD
Epoprostenol—Haematuria—Capecitabine—esophageal cancer	0.00135	0.00465	CcSEcCtD
Epoprostenol—Epistaxis—Capecitabine—esophageal cancer	0.00134	0.0046	CcSEcCtD
Epoprostenol—Bradycardia—Capecitabine—esophageal cancer	0.0013	0.00446	CcSEcCtD
Epoprostenol—Myalgia—Cisplatin—esophageal cancer	0.00128	0.00441	CcSEcCtD
Epoprostenol—Haemoglobin—Capecitabine—esophageal cancer	0.00128	0.0044	CcSEcCtD
Epoprostenol—Rhinitis—Capecitabine—esophageal cancer	0.00128	0.00439	CcSEcCtD
Epoprostenol—Anxiety—Cisplatin—esophageal cancer	0.00128	0.00439	CcSEcCtD
Epoprostenol—Haemorrhage—Capecitabine—esophageal cancer	0.00128	0.00438	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00127	0.00438	CcSEcCtD
Epoprostenol—Hypoaesthesia—Capecitabine—esophageal cancer	0.00127	0.00436	CcSEcCtD
Epoprostenol—Pharyngitis—Capecitabine—esophageal cancer	0.00127	0.00435	CcSEcCtD
Epoprostenol—Oedema peripheral—Capecitabine—esophageal cancer	0.00126	0.00432	CcSEcCtD
Epoprostenol—Connective tissue disorder—Capecitabine—esophageal cancer	0.00125	0.00431	CcSEcCtD
Epoprostenol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00123	0.00422	CcSEcCtD
Epoprostenol—Oedema—Cisplatin—esophageal cancer	0.00123	0.00422	CcSEcCtD
Epoprostenol—Infection—Cisplatin—esophageal cancer	0.00122	0.0042	CcSEcCtD
Epoprostenol—Nervous system disorder—Cisplatin—esophageal cancer	0.00121	0.00414	CcSEcCtD
Epoprostenol—Thrombocytopenia—Cisplatin—esophageal cancer	0.0012	0.00413	CcSEcCtD
Epoprostenol—Tachycardia—Cisplatin—esophageal cancer	0.0012	0.00412	CcSEcCtD
Epoprostenol—Skin disorder—Cisplatin—esophageal cancer	0.00119	0.0041	CcSEcCtD
Epoprostenol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00119	0.00408	CcSEcCtD
Epoprostenol—Flushing—Capecitabine—esophageal cancer	0.00118	0.00407	CcSEcCtD
Epoprostenol—Cardiac disorder—Capecitabine—esophageal cancer	0.00118	0.00407	CcSEcCtD
Epoprostenol—Anorexia—Cisplatin—esophageal cancer	0.00117	0.00403	CcSEcCtD
Epoprostenol—Angiopathy—Capecitabine—esophageal cancer	0.00116	0.00398	CcSEcCtD
Epoprostenol—Mediastinal disorder—Capecitabine—esophageal cancer	0.00115	0.00395	CcSEcCtD
Epoprostenol—Hypotension—Cisplatin—esophageal cancer	0.00115	0.00395	CcSEcCtD
Epoprostenol—Chills—Capecitabine—esophageal cancer	0.00114	0.00393	CcSEcCtD
Epoprostenol—Abdominal discomfort—Methotrexate—esophageal cancer	0.00114	0.00391	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—esophageal cancer	0.00113	0.00387	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00112	0.00385	CcSEcCtD
Epoprostenol—Mental disorder—Capecitabine—esophageal cancer	0.00112	0.00384	CcSEcCtD
Epoprostenol—Paraesthesia—Cisplatin—esophageal cancer	0.0011	0.00379	CcSEcCtD
Epoprostenol—Dyspnoea—Cisplatin—esophageal cancer	0.0011	0.00377	CcSEcCtD
Epoprostenol—Flatulence—Capecitabine—esophageal cancer	0.00109	0.00376	CcSEcCtD
Epoprostenol—Back pain—Capecitabine—esophageal cancer	0.00107	0.00369	CcSEcCtD
Epoprostenol—Decreased appetite—Cisplatin—esophageal cancer	0.00107	0.00367	CcSEcCtD
Epoprostenol—Muscle spasms—Capecitabine—esophageal cancer	0.00107	0.00367	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—esophageal cancer	0.00106	0.00365	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00106	0.00365	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—esophageal cancer	0.00106	0.00363	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—esophageal cancer	0.00106	0.00363	CcSEcCtD
Epoprostenol—Depression—Methotrexate—esophageal cancer	0.00105	0.00362	CcSEcCtD
Epoprostenol—Pain—Cisplatin—esophageal cancer	0.00105	0.00361	CcSEcCtD
Epoprostenol—Tremor—Capecitabine—esophageal cancer	0.00104	0.00357	CcSEcCtD
Epoprostenol—Anaemia—Capecitabine—esophageal cancer	0.00103	0.00353	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—esophageal cancer	0.00101	0.00348	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—esophageal cancer	0.00101	0.00346	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—esophageal cancer	0.000997	0.00343	CcSEcCtD
Epoprostenol—Syncope—Capecitabine—esophageal cancer	0.000996	0.00342	CcSEcCtD
Epoprostenol—Palpitations—Capecitabine—esophageal cancer	0.000981	0.00337	CcSEcCtD
Epoprostenol—Loss of consciousness—Capecitabine—esophageal cancer	0.000976	0.00335	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—esophageal cancer	0.000972	0.00334	CcSEcCtD
Epoprostenol—Cough—Capecitabine—esophageal cancer	0.000969	0.00333	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—esophageal cancer	0.000954	0.00328	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—esophageal cancer	0.000949	0.00326	CcSEcCtD
Epoprostenol—Arthralgia—Capecitabine—esophageal cancer	0.000945	0.00325	CcSEcCtD
Epoprostenol—Chest pain—Capecitabine—esophageal cancer	0.000945	0.00325	CcSEcCtD
Epoprostenol—Myalgia—Capecitabine—esophageal cancer	0.000945	0.00325	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—esophageal cancer	0.000942	0.00324	CcSEcCtD
Epoprostenol—Anxiety—Capecitabine—esophageal cancer	0.000942	0.00324	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000939	0.00323	CcSEcCtD
Epoprostenol—Dry mouth—Capecitabine—esophageal cancer	0.000924	0.00318	CcSEcCtD
Epoprostenol—Confusional state—Capecitabine—esophageal cancer	0.000914	0.00314	CcSEcCtD
Epoprostenol—Oedema—Capecitabine—esophageal cancer	0.000906	0.00311	CcSEcCtD
Epoprostenol—Hypersensitivity—Cisplatin—esophageal cancer	0.000906	0.00311	CcSEcCtD
Epoprostenol—Infection—Capecitabine—esophageal cancer	0.0009	0.00309	CcSEcCtD
Epoprostenol—Shock—Capecitabine—esophageal cancer	0.000891	0.00306	CcSEcCtD
Epoprostenol—Nervous system disorder—Capecitabine—esophageal cancer	0.000888	0.00305	CcSEcCtD
Epoprostenol—Thrombocytopenia—Capecitabine—esophageal cancer	0.000887	0.00305	CcSEcCtD
Epoprostenol—Tachycardia—Capecitabine—esophageal cancer	0.000884	0.00304	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—esophageal cancer	0.000882	0.00303	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—esophageal cancer	0.000881	0.00303	CcSEcCtD
Epoprostenol—Skin disorder—Capecitabine—esophageal cancer	0.00088	0.00302	CcSEcCtD
Epoprostenol—Hyperhidrosis—Capecitabine—esophageal cancer	0.000876	0.00301	CcSEcCtD
Epoprostenol—Anorexia—Capecitabine—esophageal cancer	0.000864	0.00297	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—esophageal cancer	0.000861	0.00296	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000856	0.00294	CcSEcCtD
Epoprostenol—Chills—Methotrexate—esophageal cancer	0.000852	0.00293	CcSEcCtD
Epoprostenol—Hypotension—Capecitabine—esophageal cancer	0.000847	0.00291	CcSEcCtD
Epoprostenol—Diarrhoea—Cisplatin—esophageal cancer	0.000841	0.00289	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—esophageal cancer	0.000832	0.00286	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000825	0.00284	CcSEcCtD
Epoprostenol—Insomnia—Capecitabine—esophageal cancer	0.000819	0.00282	CcSEcCtD
Epoprostenol—Paraesthesia—Capecitabine—esophageal cancer	0.000814	0.0028	CcSEcCtD
Epoprostenol—Dyspnoea—Capecitabine—esophageal cancer	0.000808	0.00278	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—esophageal cancer	0.000799	0.00275	CcSEcCtD
Epoprostenol—Dyspepsia—Capecitabine—esophageal cancer	0.000798	0.00274	CcSEcCtD
Epoprostenol—Decreased appetite—Capecitabine—esophageal cancer	0.000788	0.00271	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000782	0.00269	CcSEcCtD
Epoprostenol—Vomiting—Cisplatin—esophageal cancer	0.000781	0.00269	CcSEcCtD
Epoprostenol—Fatigue—Capecitabine—esophageal cancer	0.000781	0.00268	CcSEcCtD
Epoprostenol—Rash—Cisplatin—esophageal cancer	0.000775	0.00266	CcSEcCtD
Epoprostenol—Pain—Capecitabine—esophageal cancer	0.000775	0.00266	CcSEcCtD
Epoprostenol—Constipation—Capecitabine—esophageal cancer	0.000775	0.00266	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—esophageal cancer	0.000774	0.00266	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—esophageal cancer	0.000764	0.00262	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000741	0.00255	CcSEcCtD
Epoprostenol—Nausea—Cisplatin—esophageal cancer	0.00073	0.00251	CcSEcCtD
Epoprostenol—Cough—Methotrexate—esophageal cancer	0.000721	0.00248	CcSEcCtD
Epoprostenol—Urticaria—Capecitabine—esophageal cancer	0.00072	0.00247	CcSEcCtD
Epoprostenol—Abdominal pain—Capecitabine—esophageal cancer	0.000716	0.00246	CcSEcCtD
Epoprostenol—Body temperature increased—Capecitabine—esophageal cancer	0.000716	0.00246	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—esophageal cancer	0.000704	0.00242	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—esophageal cancer	0.000704	0.00242	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—esophageal cancer	0.000704	0.00242	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000699	0.0024	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—esophageal cancer	0.00068	0.00234	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—esophageal cancer	0.000674	0.00232	CcSEcCtD
Epoprostenol—Infection—Methotrexate—esophageal cancer	0.00067	0.0023	CcSEcCtD
Epoprostenol—Hypersensitivity—Capecitabine—esophageal cancer	0.000667	0.00229	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—esophageal cancer	0.000661	0.00227	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—esophageal cancer	0.00066	0.00227	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—esophageal cancer	0.000655	0.00225	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000652	0.00224	CcSEcCtD
Epoprostenol—Asthenia—Capecitabine—esophageal cancer	0.00065	0.00223	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—esophageal cancer	0.000643	0.00221	CcSEcCtD
Epoprostenol—Pruritus—Capecitabine—esophageal cancer	0.000641	0.0022	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—esophageal cancer	0.00063	0.00217	CcSEcCtD
Epoprostenol—Diarrhoea—Capecitabine—esophageal cancer	0.00062	0.00213	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000614	0.00211	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—esophageal cancer	0.00061	0.0021	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—esophageal cancer	0.000606	0.00208	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—esophageal cancer	0.000601	0.00207	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—esophageal cancer	0.0006	0.00206	CcSEcCtD
Epoprostenol—Dizziness—Capecitabine—esophageal cancer	0.000599	0.00206	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—esophageal cancer	0.000594	0.00204	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—esophageal cancer	0.000586	0.00201	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000582	0.002	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—esophageal cancer	0.000581	0.002	CcSEcCtD
Epoprostenol—Pain—Methotrexate—esophageal cancer	0.000577	0.00198	CcSEcCtD
Epoprostenol—Vomiting—Capecitabine—esophageal cancer	0.000576	0.00198	CcSEcCtD
Epoprostenol—Rash—Capecitabine—esophageal cancer	0.000571	0.00196	CcSEcCtD
Epoprostenol—Dermatitis—Capecitabine—esophageal cancer	0.000571	0.00196	CcSEcCtD
Epoprostenol—Headache—Capecitabine—esophageal cancer	0.000568	0.00195	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000552	0.0019	CcSEcCtD
Epoprostenol—Nausea—Capecitabine—esophageal cancer	0.000538	0.00185	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—esophageal cancer	0.000536	0.00184	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—esophageal cancer	0.000533	0.00183	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—esophageal cancer	0.000533	0.00183	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—esophageal cancer	0.000497	0.00171	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—esophageal cancer	0.000484	0.00166	CcSEcCtD
Epoprostenol—PTGIS—Disease—B2M—esophageal cancer	0.00048	0.000818	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GNG7—esophageal cancer	0.000478	0.000815	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GNG7—esophageal cancer	0.000478	0.000815	CbGpPWpGaD
Epoprostenol—Pruritus—Methotrexate—esophageal cancer	0.000477	0.00164	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—FKBP1A—esophageal cancer	0.000476	0.000812	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—ANXA1—esophageal cancer	0.000468	0.000799	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—WIF1—esophageal cancer	0.000465	0.000794	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL2—esophageal cancer	0.000463	0.000791	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000463	0.000791	CbGpPWpGaD
Epoprostenol—Diarrhoea—Methotrexate—esophageal cancer	0.000461	0.00159	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GNG7—esophageal cancer	0.000461	0.000787	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—WWOX—esophageal cancer	0.00046	0.000786	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—WWOX—esophageal cancer	0.00046	0.000786	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ENO1—esophageal cancer	0.00046	0.000785	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL2—esophageal cancer	0.000457	0.00078	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—SST—esophageal cancer	0.000455	0.000777	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PSME1—esophageal cancer	0.000453	0.000773	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PSME2—esophageal cancer	0.000453	0.000773	CbGpPWpGaD
Epoprostenol—Dizziness—Methotrexate—esophageal cancer	0.000446	0.00153	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—GHRL—esophageal cancer	0.000444	0.000757	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FKBP1A—esophageal cancer	0.000438	0.000747	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FKBP1A—esophageal cancer	0.000438	0.000747	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CALR—esophageal cancer	0.000435	0.000742	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALDH2—esophageal cancer	0.000432	0.000737	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000431	0.000735	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—ANXA1—esophageal cancer	0.000431	0.000735	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CSNK1A1—esophageal cancer	0.000429	0.000732	CbGpPWpGaD
Epoprostenol—Vomiting—Methotrexate—esophageal cancer	0.000429	0.00147	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—WIF1—esophageal cancer	0.000428	0.00073	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—WIF1—esophageal cancer	0.000428	0.00073	CbGpPWpGaD
Epoprostenol—Rash—Methotrexate—esophageal cancer	0.000425	0.00146	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—ANXA1—esophageal cancer	0.000425	0.000725	CbGpPWpGaD
Epoprostenol—Dermatitis—Methotrexate—esophageal cancer	0.000425	0.00146	CcSEcCtD
Epoprostenol—Headache—Methotrexate—esophageal cancer	0.000423	0.00145	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL2—esophageal cancer	0.000421	0.000718	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL2—esophageal cancer	0.000421	0.000718	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FBXW7—esophageal cancer	0.000421	0.000718	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—SST—esophageal cancer	0.000419	0.000715	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—SST—esophageal cancer	0.000419	0.000715	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—SST—esophageal cancer	0.000414	0.000706	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTT1—esophageal cancer	0.000411	0.000701	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GHRL—esophageal cancer	0.000408	0.000697	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—GHRL—esophageal cancer	0.000408	0.000697	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000408	0.000697	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP2A6—esophageal cancer	0.000406	0.000693	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000405	0.000691	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—GHRL—esophageal cancer	0.000403	0.000688	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PFN1—esophageal cancer	0.000401	0.000685	CbGpPWpGaD
Epoprostenol—Nausea—Methotrexate—esophageal cancer	0.000401	0.00138	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000395	0.000674	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CSNK1A1—esophageal cancer	0.000395	0.000674	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NOS2—esophageal cancer	0.000394	0.000672	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—ANXA1—esophageal cancer	0.000391	0.000668	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ANXA1—esophageal cancer	0.000391	0.000668	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000388	0.000663	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS1—esophageal cancer	0.000385	0.000657	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ENO1—esophageal cancer	0.000385	0.000657	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000384	0.000655	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—SST—esophageal cancer	0.000381	0.000649	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—SST—esophageal cancer	0.000381	0.000649	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PSME1—esophageal cancer	0.000379	0.000648	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PSME2—esophageal cancer	0.000379	0.000648	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000375	0.000639	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000375	0.000639	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GHRL—esophageal cancer	0.000371	0.000633	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GHRL—esophageal cancer	0.000371	0.000633	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PFN1—esophageal cancer	0.000369	0.00063	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PFN1—esophageal cancer	0.000369	0.00063	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000364	0.000621	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000363	0.00062	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NOS2—esophageal cancer	0.000362	0.000618	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ELMO1—esophageal cancer	0.000361	0.000615	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—CREBBP—esophageal cancer	0.000354	0.000603	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKAP13—esophageal cancer	0.000352	0.000601	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000346	0.00059	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFBR2—esophageal cancer	0.00034	0.00058	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ELMO1—esophageal cancer	0.000332	0.000566	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ELMO1—esophageal cancer	0.000332	0.000566	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000331	0.000565	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP1B1—esophageal cancer	0.000327	0.000559	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—CREBBP—esophageal cancer	0.000325	0.000555	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000325	0.000555	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000325	0.000555	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKAP13—esophageal cancer	0.000324	0.000554	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKAP13—esophageal cancer	0.000324	0.000554	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PDE4D—esophageal cancer	0.000322	0.00055	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SMAD4—esophageal cancer	0.000322	0.000549	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NOS3—esophageal cancer	0.000317	0.00054	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000309	0.000528	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP19A1—esophageal cancer	0.000308	0.000525	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GNG7—esophageal cancer	0.000307	0.000523	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000305	0.000521	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000299	0.000511	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000299	0.000511	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000298	0.000509	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PDE4D—esophageal cancer	0.000297	0.000506	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PDE4D—esophageal cancer	0.000297	0.000506	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NOS3—esophageal cancer	0.000291	0.000497	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000291	0.000496	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—XIAP—esophageal cancer	0.000287	0.00049	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000287	0.00049	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GNG7—esophageal cancer	0.000282	0.000482	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GNG7—esophageal cancer	0.000282	0.000482	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—HMOX1—esophageal cancer	0.000281	0.000479	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000276	0.00047	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNA1—esophageal cancer	0.000272	0.000464	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL2—esophageal cancer	0.00027	0.000461	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ABCB1—esophageal cancer	0.00027	0.00046	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—XIAP—esophageal cancer	0.000264	0.000451	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—XIAP—esophageal cancer	0.000264	0.000451	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HIF1A—esophageal cancer	0.000263	0.00045	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PSME1—esophageal cancer	0.000252	0.000431	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PSME2—esophageal cancer	0.000252	0.000431	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ANXA1—esophageal cancer	0.000251	0.000429	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNA1—esophageal cancer	0.00025	0.000427	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNA1—esophageal cancer	0.00025	0.000427	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL2—esophageal cancer	0.000249	0.000424	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL2—esophageal cancer	0.000249	0.000424	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SST—esophageal cancer	0.000244	0.000417	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—EP300—esophageal cancer	0.000241	0.000411	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS2—esophageal cancer	0.00024	0.000409	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GHRL—esophageal cancer	0.000238	0.000406	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH3—esophageal cancer	0.000238	0.000406	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOTCH1—esophageal cancer	0.000237	0.000405	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FBXW7—esophageal cancer	0.000234	0.0004	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSME2—esophageal cancer	0.000232	0.000396	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSME1—esophageal cancer	0.000232	0.000396	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSME1—esophageal cancer	0.000232	0.000396	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSME2—esophageal cancer	0.000232	0.000396	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ANXA1—esophageal cancer	0.000231	0.000394	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ANXA1—esophageal cancer	0.000231	0.000394	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SST—esophageal cancer	0.000225	0.000384	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SST—esophageal cancer	0.000225	0.000384	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—EP300—esophageal cancer	0.000222	0.000378	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GHRL—esophageal cancer	0.000219	0.000374	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH3—esophageal cancer	0.000219	0.000374	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GHRL—esophageal cancer	0.000219	0.000374	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH3—esophageal cancer	0.000219	0.000374	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FBXW7—esophageal cancer	0.000216	0.000368	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FBXW7—esophageal cancer	0.000216	0.000368	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CREBBP—esophageal cancer	0.000215	0.000367	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH2—esophageal cancer	0.000214	0.000364	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000204	0.000348	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000202	0.000344	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH2—esophageal cancer	0.000197	0.000335	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH2—esophageal cancer	0.000197	0.000335	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS3—esophageal cancer	0.000193	0.000329	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFBR2—esophageal cancer	0.000189	0.000323	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CREBBP—esophageal cancer	0.00018	0.000308	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—esophageal cancer	0.00018	0.000308	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMAD4—esophageal cancer	0.000179	0.000306	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—esophageal cancer	0.000178	0.000304	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—esophageal cancer	0.000176	0.000301	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000176	0.0003	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFBR2—esophageal cancer	0.000174	0.000297	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFBR2—esophageal cancer	0.000174	0.000297	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—esophageal cancer	0.000172	0.000294	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMAD4—esophageal cancer	0.000165	0.000282	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMAD4—esophageal cancer	0.000165	0.000282	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—esophageal cancer	0.000164	0.00028	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NOS3—esophageal cancer	0.000161	0.000275	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—esophageal cancer	0.000159	0.000271	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000156	0.000267	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000156	0.000267	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1A—esophageal cancer	0.000154	0.000263	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—esophageal cancer	0.000148	0.000252	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—esophageal cancer	0.000147	0.00025	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—esophageal cancer	0.000147	0.00025	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—esophageal cancer	0.00014	0.000239	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00014	0.000238	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—esophageal cancer	0.000135	0.00023	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—esophageal cancer	0.000135	0.00023	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000133	0.000227	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA1—esophageal cancer	0.000133	0.000227	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH1—esophageal cancer	0.000132	0.000226	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—esophageal cancer	0.000129	0.00022	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—esophageal cancer	0.000129	0.00022	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—esophageal cancer	0.000128	0.000218	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—esophageal cancer	0.000125	0.000213	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—esophageal cancer	0.000123	0.000209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—esophageal cancer	0.000122	0.000208	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—esophageal cancer	0.000122	0.000208	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA2—esophageal cancer	0.000122	0.000207	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CREBBP—esophageal cancer	0.00012	0.000205	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000119	0.000203	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—esophageal cancer	0.000118	0.000201	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000113	0.000193	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000113	0.000193	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000113	0.000192	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000112	0.000191	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CREBBP—esophageal cancer	0.00011	0.000188	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CREBBP—esophageal cancer	0.00011	0.000188	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—esophageal cancer	0.000108	0.000185	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—esophageal cancer	0.000108	0.000185	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—esophageal cancer	0.000108	0.000185	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—esophageal cancer	0.000107	0.000183	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000104	0.000177	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000104	0.000177	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—esophageal cancer	0.000102	0.000174	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—esophageal cancer	0.0001	0.000171	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADH1B—esophageal cancer	9.91e-05	0.000169	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—esophageal cancer	9.88e-05	0.000169	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—esophageal cancer	9.88e-05	0.000169	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMP—esophageal cancer	9.47e-05	0.000162	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—esophageal cancer	9.41e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—esophageal cancer	9.41e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—esophageal cancer	9.24e-05	0.000158	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—esophageal cancer	9.24e-05	0.000158	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP26A1—esophageal cancer	9.21e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—esophageal cancer	9.08e-05	0.000155	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALOX15—esophageal cancer	8.98e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—esophageal cancer	8.87e-05	0.000151	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—esophageal cancer	8.58e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TPI1—esophageal cancer	8.56e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTO1—esophageal cancer	8.56e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOB—esophageal cancer	8.21e-05	0.00014	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—esophageal cancer	8.16e-05	0.000139	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—esophageal cancer	8.16e-05	0.000139	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—esophageal cancer	8.16e-05	0.000139	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GAPDH—esophageal cancer	7.9e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—esophageal cancer	7.89e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—esophageal cancer	7.89e-05	0.000135	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CRABP1—esophageal cancer	7.83e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—esophageal cancer	7.51e-05	0.000128	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—esophageal cancer	7.51e-05	0.000128	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNG7—esophageal cancer	7.45e-05	0.000127	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—esophageal cancer	7.11e-05	0.000121	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH2—esophageal cancer	6.98e-05	0.000119	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—esophageal cancer	6.96e-05	0.000119	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—esophageal cancer	6.64e-05	0.000113	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2A6—esophageal cancer	6.56e-05	0.000112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—esophageal cancer	6.55e-05	0.000112	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—esophageal cancer	6.55e-05	0.000112	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.54e-05	0.000112	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—esophageal cancer	6.4e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—esophageal cancer	6.4e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO1—esophageal cancer	6.22e-05	0.000106	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS1—esophageal cancer	6.22e-05	0.000106	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSME1—esophageal cancer	6.13e-05	0.000105	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSME2—esophageal cancer	6.13e-05	0.000105	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—esophageal cancer	6.04e-05	0.000103	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—esophageal cancer	5.84e-05	9.97e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—esophageal cancer	5.56e-05	9.48e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—esophageal cancer	5.56e-05	9.48e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—esophageal cancer	5.38e-05	9.17e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—esophageal cancer	5.38e-05	9.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.35e-05	9.14e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—esophageal cancer	5.29e-05	9.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP19A1—esophageal cancer	4.97e-05	8.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.54e-05	7.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.45e-05	7.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.36e-05	7.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.29e-05	5.62e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.91e-05	4.97e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—esophageal cancer	2.61e-05	4.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.38e-05	4.07e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—esophageal cancer	1.98e-05	3.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.47e-05	2.5e-05	CbGpPWpGaD
